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ABSTRACT 
 
TIP39 (“tuberoinfundibular peptide of 39 residues”) acts via the parathyroid hormone 2 receptor, 
PTH2, a Family B G protein-coupled receptor (GPCR). Despite the importance of GPCRs in 
human physiology and pharmacotherapy, little is known about the molecular details of the TIP39-
PTH2 interaction. To address this, we utilised the different pharmacological profiles of TIP39 and 
PTH(1-34) at PTH2 and its related receptor PTH1: TIP39 being an agonist at the former but an 
antagonist at the latter, while PTH(1-34) activates both. A total of 23 site-directed mutations of 
PTH2, in which residues were substituted to the equivalent in PTH1, were made and 
pharmacologically screened for agonist activity. Follow-up mutations were analysed by 
radioligand binding and cAMP assays. A model of the TIP39-PTH2 complex was built and 
analysed using molecular dynamics. Only Tyr318-Ile displayed reduced TIP39 potency, despite 
having increased PTH(1-34) potency, and further mutagenesis and analysis at this site 
demonstrated that this was due to reduced TIP39 affinity at Tyr318-Ile (pIC50 = 6.01±0.03) 
compared with wild type (pIC50 = 7.81±0.03). The hydroxyl group of the Tyr-318’s side chain 
was shown to be important for TIP39 binding, with the Tyr318-Phe mutant displaying 13-fold 
lower affinity and 35-fold lower potency compared with wild type. TIP39 truncated by up to 5 
residues at the N-terminus was still sensitive to the mutations at Tyr-318, suggesting that it 
interacts with a region within TIP39(6-39). Molecular modelling and molecular dynamics 
simulations suggest that the selectivity is based on an interaction between the Tyr-318 hydroxyl 
group with the carboxylate side chain of Asp-7 of the peptide. 
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1. INTRODUCTION 
The recent increase in structural information for class B GPCRs, encompassing both the 
extracellular domain and the transmembrane helical bundle, can be used to interpret 
pharmacological studies of class B peptide hormones. Here our focus is on the parathyroid 
hormone 2 receptor (PTH2), a Family B G protein-coupled receptor (GPCR) which is potently 
activated by its endogenous neuropeptide TIP39 (“tuberoinfundibular peptide of 39 residues”). 
Human PTH2 is also activated by parathyroid hormone (PTH) and indeed shares 50% sequence 
identity with PTH1, the receptor for both PTH and PTH-related peptide (PTHrP), which is why 
PTH2 was named after PTH. However, TIP39, acting through PTH2, has very distinct 
physiological roles compared with the calcium homeostasis function of PTH acting through PTH1 
– for example, TIP39 modulates various aspects of the stress response, and is also involved in 
thermoregulation, nociception, and prolactin release [reviewed in 1]. Here we seek to identify the 
key interactions that govern the selective activation of PTH2 by TIP39. 
 
Like other Family B GPCRs, PTH2 is activated by peptide agonists via a two site interaction 
model [2, 3] in which the ligand’s C-terminal α-helical region interacts with the receptor’s N-
terminal extracellular (N) domain to generate affinity, while the N-terminal region of the peptide 
activates the receptor via a second interaction with the receptor’s transmembrane helices and 
connecting loops (juxta-membrane “J” domain). The nature of the first interaction has been 
detailed via the solution of the structure of the ligand-bound extracellular domain of PTH1 via X-
ray crystallography [4]. The crystal structure showed that the ligand forms an α-helix which 
docks into a long hydrophobic groove on the N domain via hydrophobic interactions formed by 
Val-21*, Trp-23*, Leu-24*, Leu-28*, Val-31* and Phe-34* of PTH (ligand residues will be 
distinguished from receptor residues by an asterisk following the residue number). However, 
despite the solution of the crystal structure of the isolated J domain of two related family B 
GPCRs [5-7], the molecular details of the second activating interaction remain to be determined 
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due to the absence of endogenous ligands in these structures.  In the absence of a crystal structure 
of a peptide-bound Family B GPCR, some insights into how peptides bind to the J domain have 
nevertheless been gained through protein chemical and molecular pharmacological approaches. 
For example, the extreme N-terminal residues of both PTH and PTHrP have each been replaced 
by benzoylphenylalanine (BPA), and these active peptide agonist analogues have been cross-
linked to Met-425 of the receptor [8, 9], with a model generated which suggested that the N-
terminus of PTH lies across the extracellular surface of the receptor [8]. The cross-linking results 
were later refined by use of disulphide trapping, which can be more specific than BPA-based 
photoaffinity cross-linking, implying a preference for contacts between the extreme N-terminus 
of PTH with Leu-368, Try-421, Phe-424 and Met-425 [10]. The general consensus at that time, 
which predated the X-ray structures of the TM domain, was that class B receptors may bind 
peptides in a variety of ways [11, 12], and the peptide binding model based upon the cysteine 
trapping data was only refined slightly from that derived from the earlier BPA data, with the N-
terminus of the peptide interacting with the extracellular face of the TM domain, rather than 
binding deeper into the core of the helical bundle.  
 
While PTH is able to potently activate both human PTH1 and PTH2 receptors, surprisingly PTHrP 
does not activate PTH2, despite binding with moderate affinity. By using chimeric receptors and 
modified peptide ligands, it has been shown that the features responsible for the ability of PTH2 
to select against PTHrP are due to Ile-5* and Trp-23* of PTH being His-5* and Phe-23* in 
PTHrP [13].  The high affinity of PTH at PTH2 is maintained in part by the interaction between 
Trp-23* of the peptide and Val-41 in the N-domain of the receptor [4, 14].  However, this 
interaction is absent for PTHrP/PTH2 binding, due to the smaller size of Phe-23* [14], which 
results in lower affinity.  The inability of PTHrP to activate PTH2 is due to the presence of His-5* 
in PTHrP, rather than Ile-5* in PTH, which has been functionally linked through two reciprocal 
receptor studies to Ile-244 and Tyr-318 in the J domain of PTH2 [13, 15]. Interestingly, the two 
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topologically equivalent residues to Ile-244 and Tyr-318 in the glucagon receptor (Gln-232 and 
Leu-307) can be found to be in close contact with each other in the crystal structures of the latter 
[6, 7; see Figure 1A for a sequence alignment). In contrast to what has been previously suggested 
for PTH [10], the location of Ile-244 and Tyr-318 within the TM bundle implies that the N-
terminus of PTH receptor ligands may bind within the TM domain. This would be in line with 
what has been suggested for peptide binding at the glucagon and GLP-1 receptors through 
detailed and extensive mutagenesis and modelling studies [6, 16-19]. 
 
Despite the success of the chimeric and single residue-swap studies of PTH1 and PTH2 described 
above [13-15, 20], which identified PTH/PTHrP binding and selectivity determinants at PTH1 and 
PTH2, the nature of the TIP39 selection has not been explored to the same degree. While TIP39 is 
a potent agonist at PTH2, it does not activate PTH1, despite binding with moderate affinity [21]. 
Chimeric PTH1/PTH2 receptors have been used to demonstrate that the J domain of PTH1 is 
responsible for selecting against the high affinity binding of TIP39 and that this domain is likely 
to interact with the N-terminal region of the ligand [21]. The truncation of the first 6 residues of 
TIP39, to yield TIP (7-39), resulted in a peptide with no efficacy at PTH2 but increased its affinity 
at PTH1 relative to TIP39 [21], suggesting that selectivity for PTH2R activation is encoded within 
the first 6 residues of peptide.  
 
The aim of this study was to use site-directed mutagenesis to substitute selected PTH2 residues in 
the J domain, with those found in PTH1, in order to identify residues in PTH2 that play a role in 
ligand selection through the recognition of the N-terminal region of TIP39. To aid the 
interpretation of the data generated from the study, and to resolve the argument as to whether the 
PTH receptor ligands bind more deeply within the TM domain, we constructed a 3-dimensional 
model of PTH2 receptor bound with TIP39, based upon previous models of agonist-bound GLP-
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1R, and analyzed the residues that could interact with Tyr-318 using all-atom molecular dynamics 
simulations. 
 
2. METHODS 
2.1 Constructs. The full-length cDNA of human PTH1 and PTH2 (gift from GlaxoSmithKline) in 
pcDNA3 (Invitrogen, Paisley, UK) were used to express wild type receptors as described 
previously [14]. Mutant PTH2 receptors were selected (Figure 1) and generated using 
QuikChange® site-directed mutagenesis (Stratagene, La Jolla, CA, USA) and confirmed by DNA 
sequencing. These various pcDNA3 constructs were used to express the wild type human PTH1 
and PTH2 receptors, and mutant PTH2 receptors, in Human Embryonic Kidney (HEK)-293 cells. 
Residues which were predicted to be close to the extracellular ends of the TM regions of PTH2, 
and which were not conserved between PTH1 and PTH2, were targeted for site-directed 
mutagenesis. 
 
2.2 Cell culture. The HEK-293 cells were cultured in Dulbecco’s Modified Eagle’s Medium 
(DMEM, from Sigma, Poole, UK) supplemented with 10% foetal calf serum (Lonza Wokinham 
Ltd., Wokingham, UK) and containing 2 mM L-glutamine, 100 U/ml penicillin and 100 µg/ml 
streptomycin (Invitrogen, Paisley, UK). Cells were transfected with pcDNA3 containing the 
cDNA encoding the receptors, using the SuperFect® Transfection Reagent (Qiagen Ltd., 
Crawley, UK.) and stable clones were selected with G418 antibiotic (Invitrogen, Paisley, UK) as 
follows. Cells were seeded into a 25 cm2 flask containing 10 ml of media and transfected when 
they reached 50-80% confluence. To do this, 20 µl of SuperFect® was mixed with a DNA 
solution consisting of 5 µg plasmid DNA in 150 µl DMEM. The DNA was incubated with the 
reagent for 10 min at room temperature after which 1 ml of media was then added and mixed 
gently. The cells were washed once with sterile PBS (137 mM NaCl, 10 mM Phosphate, 2.7 mM 
KCl, pH 7.4; Sigma, Poole, UK) before the transfection mixture was added and incubated for 3 h 
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at 37oC. The cells were then washed 3 times with PBS before the addition of fresh media. Three 
days later, the supernatant was removed and the cells were washed with PBS before fresh media 
was added. Selection of transfected cells was achieved by addition of 800 µg ml-1 G418. The 
media, containing G418, was replaced every 3 days until individual colonies were clearly visible. 
Approximately 10-20 individual colonies were detached from the flask using trypsin, seeded in a 
fresh plate and grown to confluence.  
 
2.3 Peptides. PTH(1-34), TIP39 and rat [Nle8,21,Tyr34]rPTH(1-34)NH2 [called rPTH(1-34) 
throughout this paper] were from Bachem (Saffron Walden, UK). [Trp23,Tyr36]PTH(1-36) was 
custom synthesised by Cambridge Research Biochemicals. The five truncated TIP39 peptides 
(TIP (2-39), TIP (3-39), TIP (4-39), TIP (5-39), all with free carboxyl C-termini, were custom 
synthesised by Genosphere Biotechnologies (Paris, France) to >95% purity as analysed via RP-
HPLC (at 220 nm) and Mass Spec. The radioligand 125I-[Nle8,21,Tyr34] rat PTH(1-34)NH2 (called 
125I-rPTH(1-34) throughout the paper) was from Perkin Elmer Life and Analytical Sciences 
(Waltham, MA, USA).  
 
2.4 Radioligand binding. HEK-293 cells expressing the receptor(s) of interest were grown to 
confluence in poly-D-lysine coated 24-well plates. Radioligand and unlabelled peptides were 
made up in ‘Whole Cell Binding Buffer’ (WCBB: 100 nM NaCl, 50 mM Tric-HCl, 5 mM KCl, 2 
mM CaCl2 pH 7.7; Sigma, Poole, UK) supplemented with 5% heat inactivated horse serum and 
0.5% heat inactivated foetal calf serum. The cell culture media was removed and 150 μL of 125I-
rPTH (1-34) was then added to each well to give a final concentration of 50 pM (~50,000 cpm). 
150 μL of serially diluted unlabelled ligand (10 μM – 10 pM) were then added to each well and 
the cells incubated at room temperature for 2 hours. The cells were then washed three times with 
WCBB, lysed with 500 μL of 5M NaOH, and then the radioactivity in the cell lysate was 
measured in a gamma counter. 
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2.5 cAMP accumulation assay. The LANCE cAMP kit (PerkinElmer Life and Analytical 
Sciences) was used alongside the manufacturer’s instructions with some minor adaptations as 
described. Cells were washed and resuspended in Stimulation buffer (HBSS, 5mM HEPES, 0.1% 
BSA, 500 μM IBMX, pH 7.4; Sigma, Poole, UK) to the required concentration. The ligands were 
prepared in DMSO at 100-fold stimulation concentrations and 0.1 μL added to each well of a 
white 384-well low volume OptiPlate. 5 μL of cells were added to each well followed by 5 μL of 
Stimulation buffer containing the Alexa Fluor® 647-labelled antibody, and incubated at room 
temperature. After the cell stimulation period, 10 μL of Detection mix was added to each well and 
incubated for 1 hour at room temperature. The data shown in Tables 1-3 were generated by REW 
either at GSK (Table 1 & 2) or Leeds (Table 3). The preliminary screening data in Table 1 were 
derived using assay conditions of 10,000 cells/well and a ligand stimulation time of 30 minutes, 
with 0.005 (v/v) Alexa Fluor®. The acceptor fluorescence signal was read at 665 nm on a 
ViewLux instrument (Perkin Elmer). Based on the results of this screen, further mutagenesis of 
Tyr-318, followed by stable cell line generation, were carried out and the full dose-response data 
shown in Table 2 were generated using 5,000 cells/well and a ligand stimulation time of 20 
minutes – the change in conditions was required to reduce the assay sensitivity in order to fit 
within the window of the standard cAMP curve generated using the assay kit at that time. The 
truncated TIP39 data shown in Table 3 were generated at a later stage in Leeds and the conditions 
were also modified in order to fit within the window of the standard cAMP curve: 2500 cells/well 
and a ligand stimulation time of 10 minutes, with 0.0025 (v/v) Alexa Fluor®, read at 665 nm 
(Victor X4 plate-reader, Perkin Elmer). Note that data have only been directly compared within 
each table for which assay conditions were identical. 
2.6 Data analysis. For each individual competition binding experiment, counts were normalised 
to the maximal specific binding within each data set. IC50 values were calculated with a single site 
binding model with the Hill co-efficient constrained to 1, while EC50 values were calculated with 
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a symmetrical sigmoid function, using non-linear regression with the aid of PRISM 5.0 software 
(GraphPad Software San Diego, CA, USA). Values in the tables represent the mean with S.E.M. 
of the individual pIC50 (-Log IC50) or pEC50 values from at least three independent experiments, 
each of which was carried out with triplicate vales for each ligand concentration.  Comparisons 
with controls were assessed using a two-tailed unpaired t test using GraphPad. Curves in the 
figures represent pooled data from three independent experiments where each point is the mean of 
the normalised values with the inter-experimental standard error of the mean displayed as error 
bars.  Bmax values were calculated from rPTH(1-34) homologous binding assays using Bmax = B0  
IC50 / [L], where [L] is the concentration of free radioligand and B0 is the specific binding in the 
absence of unlabelled ligand. Bmax values were expressed as fmol of receptor per mg of 
membrane protein where the latter was calculated using a bicinchoninic acid protein assay using 
bovine serum albumin to create a standard curve. 
 
2.7. Modelling Methods.  
Agonist-bound PTH2 receptor model. All molecular modelling manipulations were carried out 
using the tools embedded within PyMOL (The PyMOL Molecular Graphics System, Version 
1.7.2.3 Schrödinger, LLC.) unless otherwise stated. The first stage was to make a homology 
model of the J domain of PTH2 from the crystal structure of the J domain of the glucagon receptor 
([6]; pdb code 4L6R) using the homology modelling server SWISS-MODEL ([22]; 
http://swissmodel.expasy.org/). In an independent step, the ligand within the PTH-bound N 
domain crystal structure of PTH1 ([4]; pdb code 3C4M) was mutated in silico to the sequence of 
TIP39 (starting at Ala-15*) and the N domain of PTH2 was built from 3C4M using SWISS-
MODEL. Since the ligand co-ordinates were stripped out during the homology modelling stage, 
these TIP39 and PTH2 fragments were then re-docked by superposing them back on the 3C4M 
template. The Dods & Donnelly model [16] of the agonist-bound GLP-1 receptor was then used 
as a scaffold from which the full-length TIP39-bound PTH2 was constructed by first 
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superimposing the PTH2 J domain model onto the corresponding 7TM region of GLP-1R, and 
then superimposing the TIP39 ligand on the GLP-1 peptide and, in doing so, orientating the N 
domain relative to the J domain. The merged fragments were saved as a single pdb file and then 
used as a template in SWISS-MODEL from which PTH2 was rebuilt, enabling the linker region 
between the domains to be constructed as a loop. Since the ligand co-ordinates were stripped out 
during the homology modelling stage, TIP39 was re-docked according to the 3C4M template and 
then manually extended along the GLP-1R peptide model trajectory. Two main constraints were 
used to guide the latter stage: (1) since Arg-190 and Lys-197 are conserved between GLP-1R and 
PTH2, and are believed to interact with Glu-3 in the former [see 16-19], the equivalent residue in 
TIP39 (Asp-6) was positioned in a similar position; (2) Ala-3 (equivalent to the first residue of 
PTH) was placed close to residues 376, 379 and 380, since the equivalent residues in PTH1 have 
been cross-linked to the extreme N-terminus of PTH [10]. The first loop of the N domain was 
constructed using PLOP [23] and model was then subjected to optimisation using the KoBaMIN 
server ([24]; http://csb.stanford.edu/kobamin) to yield the starting model for molecular dynamics 
simulations. 
 
Molecular dynamics simulations. Simulations of PTH2 in complex with two variants of TIP39 
were prepared as follows.  All the PTH2-TIP-39 complexes were embedded in a POPC bilayer 
with explicit water and ions to a final concentration of 150 mM, and simulated using ACEMD 
[25], with the AMBER 14SB [26] and lipid 14 force fields [27].The simulation protocol included 
standard steps of energy minimization, heating from 0 to 300 K, and progressive decrease of 
conformational constraints followed by the unconstrained production run. Simulation 1 contained 
the full TIP39 peptide and the production run was 442 ns. However, due to uncertainties in 
predicting the starting conformation of the N-terminal region of full length TIP-39, we decided to 
simulate variants of TIP39 with a truncated N-terminus. Simulation 2 contained PTH2 bound to 
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TIP (5-39), and the production run was 250 ns. Simulation 3 contained PTH2 with the Tyr318-Ile 
mutation and TIP(5-39) peptide, the production run was 140 ns. The initial systems dimensions 
and sizes were 88.31 Å × 88.68 Å× 138.24 Å with 98,594 atoms for simulation 1, 88.03 Å × 
88.39 Å× 134.24 Å with 95,089 atoms for simulation 2, and 88.31 Å × 88.39 Å× 142.24 Å with 
101,659 atoms for simulation 3. Hydrogen bonds were defined with a donor-acceptor distance < 
3.0 Å, and an angle cut-off of 20°. The models and trajectories are available from 
ftp.essex.ac.uk/pub/oyster. 
 
3. RESULTS 
3.1 Initial pharmacological screen. A total of 25 stable cell lines were created for the initial 
screen, expressing either wild type PTH1, PTH2, or one of 23 mutant PTH2 receptors. Table 1 
shows the response generated from LANCE cAMP assays using concentrations of PTH(1-34) and 
TIP39 which had been shown to generate maximal responses in full concentration response 
experiments using these particular assay conditions (data not shown). As expected, PTH(1-34) 
was able to fully activate both PTH1 and PTH2, as well as all the 23 single mutant PTH2 
receptors. TIP39 was unable to activate PTH1 but displayed maximal activity at 22 of the 23 
mutant PTH2 receptors, the exception being Tyr-318-Ile which displayed only about 50% 
maximal activity.  
 
3.2 Tyr-318-Ile. The mutant PTH2 receptor, Tyr-318-Ile, was examined in more detail by using 
whole-cell radioligand binding assays and by generating full concentration-response curves using 
PTH(1-34), TIP39 and the affinity-optimised PTHrP analogue, Trp23-PTHrP (Table 2 and Figure 
2). The typical pharmacological profile of PTH2 was observed (Figure 2A), with high potency 
displayed for PTH(1-34) and TIP39 but no activity with Trp23-PTHrP. However, the 
pharmacological profile for Tyr-318-Ile was radically different (Figure 2B). As shown previously 
[15, 20], Tyr-318-Ile could be activated by Trp23-PTHrP while maintaining high potency for 
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PTH(1-34). However, as indicated by the initial screen, TIP39 potency was compromised and 
reduced by almost 300-fold. Radioligand binding assays showed that the affinity of TIP39 had 
been reduced by more than 60-fold due to the Tyr-318-Ile mutation (Table 2). 
 
3.3 Additional mutations at Tyr-318. In order to explore the nature of the pharmacological effects 
caused by the mutation of Tyr-318 to Ile, the site was further mutated to both Phe and Leu.  
Radio-ligand binding and LANCE cAMP assays showed that the Tyr-318-Leu mutation resulted 
in a similar TIP39 profile as Tyr-318-Ile. However, as expected, the more subtle change from Tyr 
to Phe resulted in a less severe effect compared with the substitution to Ile upon TIP39 affinity 
(13-fold compared with 62-fold) and potency (35-fold compared with 282-fold). Nevertheless, 
the reduced affinity and potency of Tyr-318-Phe compared with PTH2 suggested that the 
hydroxyl group of Tyr-318 plays a role in endogenous ligand recognition (Table 2, Figure 3). 
 
3.4 N-terminal truncations of TIP39.  In order to explore whether Tyr-318, and in particular its 
hydroxyl group, interacts with the N-terminal residues of TIP39, 5 N-terminal truncations of the 
peptide (Fig 4A) were pharmacologically analysed at PTH2, Tyr-318-Ile and Tyr-318-Phe (Table 
3). Truncation of up to 3 residues at the N-terminus of TIP39 resulted in up to only a 5-fold 
reduction in potency but the removal of the 4th residue (Leu-4*) resulted in a step-change 
reduction of almost 300-fold. Likewise, TIP39 missing the first 5 N-terminal residues had more 
than 2,000-fold lower potency compared with full-length TIP39 (Fig 4B). The reduction in 
potency observed for peptides lacking residues 4 and 5, is only partly correlated with a reduction 
in affinity, with a much smaller step change (68-fold for affinity compared with 2,138-fold for 
potency; Table 3; Fig 4B and 4C). The truncated TIP39 peptides displayed a similar profile at 
Tyr-318-Phe and Tyr-318-Ile, albeit with right-shifted curves, demonstrating that the mutations 
had affected all the peptides to a similar degree and that peptides lacking residue 4, or residues 4 
& 5, have severely impaired potency at both the wild type and mutant receptors (Table 3; Fig 4).  
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3.5. Molecular modelling and molecular dynamics simulations. The initial starting model for the 
TIP39-PTH2 complex resembled that of the GLP-1R template used [16] in terms of the relative 
positioning of the N and J domains and on the placement of the helical region of the peptide 
ligand. However, while the N-terminal region of the ligand in the GLP-1R template was modelled 
on the β-coil region of the related ligand PACAP21 (pdb code 1GEA), the absence of sequence 
conservation in TIP39 and its longer length (3 residues longer than GLP-1) resulted in the need to 
build this region ab initio, with the guidance of two constraints. Firstly, the Glu-9* to Arg-190 
interaction [16, 19] between GLP-1 and GLP-1R was emulated in the TIP-39-PTH2 model 
through an interaction between Asp-6*-Arg-190 and, indeed, this interaction was maintained in 
the dynamics simulation (Figure 6C), in the same way as the analogous interaction was also 
stable in simulations of GLP-1R with GLP-1 [19]. Secondly, Ala-3* in TIP39 (equivalent to the 
first residue of PTH) was placed close to PTH2 residues 376, 379 and 380, since the extreme N-
terminus of PTH has been cross-linked to these sites in PTH1 [10]. However, the ambiguity and 
sporadic nature of the initial simulations of full-length PTH2 bound to full-length TIP-39 (data not 
shown) led us to believe that the subjective modelling of the peptide’s extreme N-terminus was 
problematic. To address this, we prepared further simulations of PTH2 with a truncated N-
terminus, TIP (5-39), which showed a stable pattern of hydrogen bonding of Tyr-318 with residue 
Asp-7* of TIP39 (Figures 5 and 6).  
 
In addition to the Asp-6*-Arg190 (2x60) interaction, the molecular dynamics predicted a number 
of other interactions in the TM domain binding pocket that were observed with significant 
frequency during the simulations (Figure 7). For example, the hydrogen bond between Asp-7* 
and Tyr-318 (5x39) is supplemented by an additional interaction between the Asp-7* and Gln-
319 (5x40). Arg13* can interact with either with Gln-138 (1x33) or Glu-139 (1x34) at the top of 
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TM1, and also with Glu-392 (7x49) at the top of TM7. In addition, hydrophobic interactions were 
observed between Ala-9* and Leu-399 (7x42) and between Phe-10* and Phe-141 (1x36). 
4. DISCUSSION AND CONCLUSIONS 
Both human PTH1 and PTH2 receptors are activated by PTH, suggesting that they share similar 
ligand binding sites and are activated by equivalent mechanisms.  However, TIP39, the potent 
PTH2 agonist and endogenous PTH2 ligand, does not appreciably activate PTH1, despite binding 
to it with moderate affinity [21]. Chimeric PTH1/PTH2 receptors, in which the N and J domains 
were exchanged, have been used to demonstrate that it is the J domain which is responsible for 
interacting with the N-terminal region of TIP39 and for providing the observed selective binding 
[13, 14]. Hence, we have substituted selected PTH2 residues with those found in PTH1 and have 
identified Tyr-318 as the key residue position responsible for the observed reduction in reduced 
TIP39 activity. The results of the modelling and molecular dynamic simulations suggest that the 
N-terminus of the peptide binds within the helical bundle of the J domain, and that Asp-7* is the 
most likely interaction partner of Tyr-318 since its hydroxyl group can form an hydrogen bond 
with the carboxylate group of Asp-7*, which persists during the MD simulations on the truncated 
peptide, TIP39(5-39), despite the dramatically reduced affinity of this peptide.  
 
Residues predicted to be close to the extracellular ends of the TM regions of PTH2, and which 
were not conserved between PTH1 and PTH2, were targeted for site-directed mutagenesis. The 
start of this study preceded the solution of the first crystal structures of the J domain [5-7], and 
hence the TM boundaries were predictions but nevertheless largely match those revealed by the 
crystal structures (Figure 1; TM boundaries shown are based on [6]). The 23 mutant receptors 
generated were screened using a cAMP assay in order to identify any mutations which had 
reduced TIP39 activity. As expected, given that both human PTH1 and PTH2 are activated by 
PTH, all the mutant receptors maintained full activity when exposed to 1 μM PTH. In hindsight, 
given the subsequent publication of the crystal structures, many of the residues targeted were 
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facing away from the centre of the helical bundle and hence would be expected not to contribute 
directly to peptide binding. However, of the 6 internally-facing residues targeted for mutagenesis, 
only the Tyr-318-Ile mutation displayed reduced activity to 10 nM TIP39 and was hence 
examined in more detail. 
 
Tyr-318-Ile in PTH2 has been identified previously as one of two sites responsible for enabling 
the receptor to select against PTHrP, probably through interacting with residue 5 of PTH and 
PTHrP [15]. Using Trp23-PTHrP (the Phe-23* to Trp modification enables higher affinity 
binding to PTH2 [13, 15]), the ability of the Tyr-318-Ile mutation to enable Trp23-PTHrP 
activation can be clearly observed using full concentration response curves (Figure 2). However, 
we show for the first time here that the same mutation results in a substantial reduction in TIP39 
potency (>280-fold) and affinity (>60-fold), yielding a receptor with substantially altered 
pharmacology from wild type PTH2 (compare Figure 2A and 2B).  
 
In order to explore the mechanism underlying this altered pharmacological profile, we examined 
two further substitutions of Tyr-318, mutated to Phe and Leu, using radioligand binding assays 
and functional cAMP assays. Both Tyr-318-Leu and Tyr-318-Phe displayed high potency for 
PTH(1-34) and also rescued potency for Trp23-PTHrP, albeit both at a lower potency compared 
with Tyr-318-Leu, which has the substitution to the native PTH1 residue (Table 2). The Tyr-318-
Leu receptor displayed similarly impaired TIP39 pharmacology as Tyr-318-Ile, with a TIP39 
potency reduction of 437-fold and affinity reduction of 44-fold. The more subtle substitution of 
Tyr-318 with Phe, removing a single hydroxyl group, nevertheless resulted in a mutant receptor 
with 35-fold reduced potency and 13-fold reduced affinity for TIP39 compared with wild type 
PTH2. Hence we conclude that Tyr-318 takes part in an interaction that optimises the binding and 
activation pocket for TIP39 and that its hydroxyl group forms part of this interaction. 
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Given that the truncation of the first 6 residues of TIP39, to yield TIP (7-39), resulted in a peptide 
with no observable efficacy at PTH2 [21], we explored the possibility that the interaction formed 
by Tyr-318 may be via these first 6 residues. Indeed, the removal of 4 or 5 residues from TIP39 
resulted in a peptide with a reduced affinity that approximates (about 60-fold) to that observed 
when the hydroxyl group of Tyr-318 is removed (Tables 2 and 3). We hypothesised that a direct 
interaction between PTH2 and a particular N-terminal residue on the ligand would be revealed if 
the removal of that residue led to no detectable change in affinity/potency when comparing wild 
type PTH2 and a Tyr-318 mutant - the logic being that if the interacting residue was already 
absent from the ligand (due to truncation), then the removal of the Tyr-318 interaction site would 
result in no additional change in affinity/potency. However, the Tyr-318-Ile and Tyr-318-Phe 
mutations affected all the truncated TIP39 analogues used, including TIP(6-39), suggesting that 
Tyr-318 interacts with a residue within the 6-39 region. The absence of potency for TIP39 peptide 
analogues truncated beyond this point [21] makes it difficult to explore this possibility 
experimentally, and hence we have used a computational approach to explore the hypothesis that 
Tyr-318 may interact with Asp-7*, the topologically equivalent site to reside 5* of PTH and 
PTHrP that has previously been shown to be functionally linked to Tyr-318 [15]. There had been 
an earlier attempt [28] to model TIP39 binding to PTH2 which suggested that Asp-7* interacts 
with His-396 on TM7. However, this study pre-dated the solution of the structure of any Family 
B J domain and the new information suggests that His-396 is positioned at the TM1-TM7 
interface and quite distant from Asp-7*. Our modelling has enabled the predictions of a dual 
interaction between Asp-6* and Arg-190 and between Asp-7* and Tyr-318 which, coupled with 
the cross-linking data [8-10], makes the PTH1/PTH2 system particularly well characterized for 
class B receptors. Truncation of Asp-6* led to a complete loss of activity [21] and our model 
suggests it plays a key role through binding to Arg190 – indeed, this interaction may be quite 
general amongst class B GPCR ligands as several have a residue similar to Asp-6* at this position 
[30].  
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In summary, we have analysed 23 sites within the PTH2 receptor and identified Tyr-318 as 
playing an important role in the interaction of the endogenous TIP39 agonist with its receptor, 
given that its substitution with Ile or Leu results in a 282-437-fold reduction in potency and a 44-
62 fold reduction in affinity. The hydroxyl group of Tyr-318 is involved in this interaction since 
its removal resulted in a 35-fold reduced potency and 13-fold reduced affinity for TIP39. To our 
knowledge, this is the first reported PTH2 receptor residue shown to interact with its endogenous 
agonist TIP39 and its identification, alongside our model based upon the latest crystallographic 
data for Family B GPCRs, enabled us to suggest a binding model for the N-terminus of TIP39 
within the TM domain of PTH2. The interaction of Tyr-318 is likely to be with the N-terminal 
region of TIP39, although not with residues 1-5. Given the outcome of the molecular modelling 
and molecular dynamics study, coupled with alignment of Asp-7* in TIP39 with His-5* in PTHrP 
and Ile-5* in PTH, we propose that the most likely candidate to interact with Tyr-318 is Asp-7*. 
The simulations also identified Asp-6* as a likely binding partner of Arg-190, as also observed in 
GLP-1R [16] and in the VPAC receptor [31, 32]. 
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Table 1:  
 
 Receptor  % maximum PTH (1-34) response 
  
1µM PTH(1-34) 10nM TIP-39 
PTH1  99 ± 2 1 ± 2 
PTH2  102 ± 1 98 ± 2 
PTH2R (V146M) 1x41 102 ± 1 103 ± 1 
PTH2R (M147I) 1x42 103 ± 2 100 ± 2 
PTH2R (I154V) 1x49 104 ± 3 103 ± 5 
PTH2R (V185L) 2x55 105 ± 2 104 ± 4 
PTH2R (T192V) 2x62 102 ± 2 99 ± 1 
PTH2R (I238V) 3x31 104 ± 2 97 ± 2 
PTH2R (V241T) 3x34 100 ± 1 97 ± 2 
PTH2R (M242F) 3x35 98 ± 2 98 ± 2 
PTH2R (I244L)  3x37 100 ± 3 106 ± 4 
PTH2R (A293V) 4x59 99 ± 2 97 ± 1 
PTH2R (A295V) 4x61 99 ± 2 98 ± 1 
PTH2R (V296S) 4x62 101 ± 2 101 ± 3 
PTH2R (A297V) 4x63 100 ± 2 99 ± 1 
PTH2R (Y318I)  5x39 99 ± 1 51 ± 6** 
PTH2R (A320V) 5x41 100 ± 1 97 ± 2 
PTH2R (A325S) 5x46 103 ± 2 100 ± 2 
PTH2R (G327V) 5x48 100 ± 2 99 ± 2 
PTH2R (V380M) 6x57 102 ± 1 102 ± 1 
PTH2R (C381A) 6x58 100 ± 2 101 ± 2 
PTH2R (L382T) 6x59 102 ± 2 103 ± 2 
PTH2R (C397Y) 7x40 100 ± 2 98 ± 1 
PTH2R (L399M) 7x42 101 ± 1 98 ± 2 
PTH2R (F400L) 7x43 104 ± 2 105 ± 3 
 
Table 1: cAMP assays of wild type PTH1 and PTH2, and 23 mutated PTH2 receptors substituted 
at the sites indicated in Figure 1 (single letter amino acid codes are shown here with Wootten 
numbering in column 2 [26]). Values are the % of the mean maximal PTH(1-34) response using 
either 1 μM PTH(1-34) left, or 10 nM TIP39 right. One residue (Tyr-318-Ile) displays reduced 
TIP39 activity. **Significantly different to PTH2 (P ≤  0.002). 
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Table 2:  
 pEC
50 
(EC50 / nM)
 
 pIC
50 
(IC50 / nM)
 
B
max 
/ amol cell -1 
  
PTH (1-34) 
 
Trp23-PTHrP 
 
TIP-39 
  
TIP-39 
 
       
PTH
2
 8.39 ± 0.28 
(4.1) 
ND 9.14 ± 0.35 
(0.7) 
 7.81 ± 0.02 
(15.5) 
13.3 ± 2.4 
Tyr-318-Phe 8.17 ± 0.30 
(6.8) 
5.84 ± 0.15 
(1445.4) 
7.60 ± 0.22* 
(25.1) 
 6.70 ± 0.16** 
(199.5) 
10.7 ± 2.4 
Tyr-318-Leu 8.66 ± 0.22 
(2.2) 
6.09 ± 0.20 
(812.8) 
6.50 ± 0.09** 
(316.2) 
 6.17 ± 0.08** 
(676.1) 
12.3 ± 2.2 
Tyr-318-Ile 9.45 ± 0.08 
(0.4) 
7.39 ± 0.08 
(40.7) 
6.69 ± 0.03** 
(204.2) 
 6.02 ± 0.03** 
(955.0) 
21.3 ± 7.7 
 
Table 2: Pharmacological data for various peptide ligands at wild type PTH2 and three mutated 
PTH2 receptors, as indicated. Values represent mean pEC50 and pIC50 values ± S.E.M. for three 
independent experiments, with the corresponding EC50 or IC50 values (nM) shown below in 
brackets. Bmax were derived from three independent homologous radioligand competition binding 
assays using the radioligand 125I-rPTH (1-34). Significantly different from PTH2 with the TIP-39: 
* P ≤  0.02; ** P ≤ 0.002) 
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Table 3:  
 
pEC50 
(EC50 / nM)
 
 
PTH
2
 Tyr-318-Phe Tyr-318-Ile 
TIP-39 
10.24 ± 0.07 
(5.75x10-2) 
9.18 ± 0.04 
(0.66) 
8.18 ± 0.09 
(6.61) 
TIP (2-39) 
9.92 ± 0.10 
(0.12) 
8.32 ± 0.11** 
(4.79) 
7.38 ± 0.17* 
(41.69) 
TIP (3-39) 
9.66 ± 0.13* 
(0.22) 
8.02 ± 0.11** 
(9.55) 
7.30 ± 0.17* 
(50.12) 
TIP (4-39) 
9.54 ± 0.14* 
(0.29) 
7.88 ± 0.20* 
(13.18) 
7.05 ± 0.14* 
(89.13) 
TIP (5-39) 
7.77 ± 0.06** 
(16.98) 
6.04 ± 0.18** 
(912.01) 
<6 
(>1000) 
TIP (6-39) 
6.91 ± 0.16** 
(123.03) 
<6 
(>1000) 
ND 
 
    
 
pIC50 
(IC50 / nM)
 
 PTH
2
 Tyr-318-Phe Tyr-318-Ile 
TIP-39 
7.81 ± 0.02 
(15.49) 
6.70 ± 0.16 
(199.53) 
6.02 ± 0.03 
(954.99) 
TIP (2-39) 
7.23 ± 0.15* 
(58.88) 
6.38 ± 0.10 
(416.87) 
5.83 ± 0.12 
(1479.11) 
TIP (3-39) 
6.98 ± 0.10** 
(104.71) 
6.32 ± 0.09 
(478.63) 
5.90 ± 0.11 
(1258.93) 
TIP (4-39) 
6.80 ± 0.04** 
(158.49) 
6.22 ± 0.11 
(602.56) 
5.83 ± 0.13 
(1479.11) 
TIP (5-39) 
6.06 ± 0.08** 
(870.96) 
5.49 ± 0.10* 
(3235.93) 
5.14 ± 0.08** 
(7244.36) 
TIP (6-39) 
5.98 ± 0.07** 
(1047.13) 
5.37 ± 0.09** 
(4265.78) 
5.06 ± 0.04** 
(8709.63) 
Table 3: Pharmacological data for TIP39 and N-terminally truncated analogues (see Figure 4A) 
at wild type PTH2 and two mutated PTH2 receptors, as indicated. Values represent mean pEC50 
and pIC50 values ± S.E.M. for three independent experiments, with the corresponding EC50 or IC50 
values (nM) shown below in brackets. Significantly different from TIP39 at the same receptor: * 
P ≤  0.02; ** P ≤ 0.002)  
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FIGURE LEGENDS 
Figure 1: A.  Sequence alignment of three Family B GPCRs: PTH2 (PTH2R_HUMAN); PTH1 
(PTH1_HUMAN); and the glucagon receptor (GLR_HUMAN).The seven transmembrane 
helices are boxed and are based on the crystal structure of the glucagon receptor [6]. The first 
and last residue number of each sequence is shown at the start and end of each line 
respectively. The residues in PTH2 which were mutated to those of PTH1 are shown bold and 
underlined. B. A schematic topological representation (generated using GPCRDB Tools, 
http://tools.gpcr.org/) of PTH2, annotated to show the regions mutated in this study (grey) with 
the residue numbers of the most interesting site highlighted. TM = transmembrane helix; ECL 
= extracellular loop. 
Figure 2: cAMP accumulation curves for HEK-293 cells expressing A PTH2 and B Tyr-318-Ile, 
using three peptide ligands as indicated in the key. Curves represent pooled data from three 
independent experiments where each point is the mean of the normalised values and inter-
experimental standard error of the mean is displayed as error bars. 
Figure 3: A cAMP accumulation and B radioligand competition binding assay, both using TIP39 
at HEK-293 cells expressing PTH2, Tyr-318-Ile, Tyr-318-Leu or Tyr-318-Phe, as indicated in 
the key. Curves represent pooled data from three independent experiments where each point is 
the mean of the normalised values and inter-experimental standard error of the mean is 
displayed as error bars. 
Figure 4: A Sequence alignment of TIP39 and the five N-terminally truncated analogues used in 
this study. B/D cAMP accumulation assays and C/E radioligand competition binding assays, 
both using HEK-293 cells expressing B/C PTH2 or D/E Tyr-318-Phe. The ligands used are 
indicated in the key in A. Curves represent pooled data from three independent experiments 
where each point is the mean of the normalised values and inter-experimental standard error of 
the mean is displayed as error bars.  
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Figure 5: A.  An overlay of the starting model of PTH2 bound to TIP (5-39) (green and orange), 
with the model following molecular dynamics simulations (cyan and yellow). B. Time 
dependent root mean square deviation (RMSD) of the backbone atoms for the full model 
(blue), the TM helices (black) and the N domain (orange) following molecular dynamics 
simulations (cyan and yellow in A) in relation to the starting structure (green and orange in A). 
C. Distance over time during molecular dynamics simulations between residue 318 (hydroxyl 
oxygen atom for Tyr or CD1 atom for Ile) and Asp-7 (CD atom) of TIP39 in the wild type 
(green) and mutant Tyr318-Ile (red) receptors. In Tyr318-Ile, Ile-318 does not interact with 
Asp-7 whereas in wild type Tyr318 and Asp-7 approached to form a stable hydrogen bond. 
 
Figure 6: A. The model from molecular dynamics simulations of PTH2 bound to TIP (5-39), 
shown in ribbon form with PTH2 (cyan) docked with TIP-39 (yellow). The boxed area shows 
the region detailed further in B., showing interactions (dashed line with distances in Å) of 
Asp-6* and Asp-7* with the receptor. C. Time-dependent number of hydrogen bonds formed 
during molecular dynamics simulations of PTH2 bound to TIP (5-39) between the indicated 
residues. Cut off values for hydrogen bonds were donor acceptor distance < 3.0 Å, and 20° for 
angle. 
 
Figure 7: A. The model from molecular dynamics simulations of PTH2 bound to TIP (5-39), 
shown in ribbon form with PTH2 docked with TIP-39, and key interacting residues shown in 
space-fill. The boxed area shows the region detailed further in B., showing predicted 
interactions between PTH2 (cyan/green) and TIP-39 (yellow) which were see with high 
frequency during the simulation. 
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FIGURE 2 
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FIGURE 3 
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FIGURE 4 
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FIGURE 5   A B 
C 
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FIGURE 6  
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